Study of Clinical and Laboratory Variables Associated With a Direct Oral Anticoagulant Bioassay Higher Among Those Aged Over 75 Years (AOD-SA)

All patients over 75 years under anticoagulant treatment 'xaban' (dabigatran, rivaroxaban, Apixaban) for atrial fibrillation, hospital unscheduled manner in Medicine and Geriatric services Versatile Service Home Emergency CHU Nantes and where a hemostatic balance is expected to be offered the study.

The recruitment will be made on a 6-month period (November 2014 - April 2015). Bioassay 'xaban' will be made from the remainder of the tube removed for hemostasis tests provided in the usual care of patients.

Inclusion Criteria:

• Age ≥ 75 years
• Entering SAU or MPG (Nantes University Hospital) as part of an unscheduled hospitalization for acute or subacute disease (About MPG, will be included patients admitted to the department within 48 hours of calling the doctor)
• In xaban to entry (dabigatran, rivaroxaban, Apixaban) for non-valvular atrial fibrillation
• In whom hemostasis tests will be prescribed as part of usual care
• Patient has given its verbal agreement

Exclusion criteria

Patients with the following criteria may not be included:

• Patients refusing to participate in the study
• Patients under guardianship
• Inability to obtain the date and time of the last dose of xaban